Our Mission

The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric, non-profit organization dedicated to speeding the delivery of innovative therapies to those living with Alzheimer’s and Parkinson’s by reducing the time and cost of Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trials.

What We Do

436 Years–That is how much clinical trial experience we bring to the table.

GAP, collectively, has expertise in nearly every area of neurology including Alzheimer’s and Parkinson’s disease, epilepsy, mental health, Down Syndrome, TBI and stroke. Finding treatments and cures for neurodegenerative diseases requires multi-layered, diverse backgrounds of clinical research, and we believe we have assembled the best team to contribute to the field

GAP works with international organizations that share our goals for clinical trial innovation. GAP regularly engages with global partners to coordinate efforts, share information and maintain open dialogue with initiatives under development around the world.

GAP Staff

Jordan Malecki


Board of Directors

Neil Buckholtz, PhD
John Dwyer
Michael J. Glosserman
Drew Holzapfel
Steven Paul
George Vradenburg
Pascale Witz

Key Advisors

Robert Alexander, MD
Mark Brody, MD
Samantha Budd Haeberlein, PhD
Jeffrey Burns, MD
Sharon Cohen, MD
Rachelle Doody, MD
Howard Fillit, MD
Michael Irizarry, MD
Lynn Kramer, MD
Mike Krautkramer, MBA
Simon Lovestone, PhD, MRCPsych
Thomas Obisesan, MD
Stephen Salloway, MD
Allison Searle, BSc
Pierre Tariot, MD
Luc Truyen, MD, PhD
Serge Van Der Geyten, PhD

Our Partners

The Global Alzheimer's Platform Foundation is grateful to be supported by the following philanthropic and industry partners

Philanthropic Partners

  • Alzheimer's Drug Discovery Foundation® (ADDF)
  • Gates Ventures
  • The Dolby Fund
  • Vradenburg Foundation

Industry Partners

To top